{'fraction_non_alphanumeric': 0.02973240832507433, 'fraction_numerical': 0.004955401387512388, 'mean_word_length': 5.733333333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Urinary excretion of beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase in advanced neuroblastoma patients receiving cis-diamminedichloroplatinum(II).

Urinary excretion of beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase (NAG) were determined in eight patients with advanced neuroblastoma receiving cis-diamminedichloroplatinum(II) (CDDP). Urinary excretion of beta 2-microglobulin was increased within 3 days after CDDP treatment and returned to its pretreatment level within the first week. Increased urinary excretion of NAG was observed until the end of the second week after CDDP administration. But the measured values on the third day after CDDP administration were not significantly correlated with the accumulated dose of CDDP administered. These results indicate that beta 2-microglobulin excretion and NAG enzymuria after CDDP treatment are sensitive parameters of acute renal tubular damage, but the long-term latent nephrotoxicity of CDDP cannot be predicted from these parameters.